اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,272
تعداد مقالات36,149
تعداد مشاهده مقاله55,713,562
تعداد دریافت فایل اصل مقاله94,492,266
Sharun, K, Jambagi, K, Arya, M, Aakanksha, ., Chaithra, S. N, Patel, P. K, Dixit, S. K, Dhama, K. (1400). Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine. سامانه مدیریت نشریات علمی, 76(5), 1175-1182. doi: 10.22092/ari.2021.356171.1797
K Sharun; K Jambagi; M Arya; . Aakanksha; S. N Chaithra; P. K Patel; S. K Dixit; K Dhama. "Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine". سامانه مدیریت نشریات علمی, 76, 5, 1400, 1175-1182. doi: 10.22092/ari.2021.356171.1797
Sharun, K, Jambagi, K, Arya, M, Aakanksha, ., Chaithra, S. N, Patel, P. K, Dixit, S. K, Dhama, K. (1400). 'Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine', سامانه مدیریت نشریات علمی, 76(5), pp. 1175-1182. doi: 10.22092/ari.2021.356171.1797
Sharun, K, Jambagi, K, Arya, M, Aakanksha, ., Chaithra, S. N, Patel, P. K, Dixit, S. K, Dhama, K. Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine. سامانه مدیریت نشریات علمی, 1400; 76(5): 1175-1182. doi: 10.22092/ari.2021.356171.1797

Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine

Archives of Razi Institute
مقاله 5، دوره 76، شماره 5، بهمن و اسفند 2021، صفحه 1175-1182    اصل مقاله (415.01 K)
نوع مقاله: Mini Review
شناسه دیجیتال (DOI): 10.22092/ari.2021.356171.1797
نویسندگان
K Sharun* 1؛ K Jambagi2؛ M Arya1؛ . Aakanksha1؛ S. N Chaithra1؛ P. K Patel2؛ S. K Dixit2؛ K Dhama3
1Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
2Division of Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
3Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
چکیده
Substance P binds to the Neurokinin-1 (NK-1) receptors found in the emetic center of the central nervous system (CNS) to induce emesis. Maropitant is a selective NK-1 receptor antagonist that inhibits the binding of substance P to NK-1 receptors and is commonly used to prevent and treat vomiting in dogs. This review study aimed to discuss and analyze the therapeutic potential of substance P (Neurokinin-1 receptor) antagonist with a particular focus on the drug maropitant in canine medicine. A systematic literature review was performed to identify the existing literature on the subject during the past 20 years (2001-2021) using such databases as ScienceDirect, PubMed, Scopus, and Google Scholar. The initial search identified 173 articles; however, 41 articles were selected for further analysis, based on the specific inclusion and exclusion criteria. Studies have already confirmed the role of substance P and NK-1 receptors in central pain processing, intestinal smooth muscle contraction, vasodilation, and neurogenic inflammation. Maropitant is one of the most effective veterinary antiemetic drugs that work well against peripheral and central stimuli that trigger the vomiting center. It has been already demonstrated that the therapeutic efficacy of maropitant for managing acute vomiting in dogs is associated with pancreatitis, gastritis, and parvoviral enteritis. It can also prevent and treat chemotherapy-induced emesis and delay the signs of nausea and adverse gastrointestinal effects. Regarding the broad-spectrum antiemetic activity of maropitant, it can be recommended for managing uremic vomiting in dogs. In addition, it has also exhibited an anesthetic sparing effect since the dogs treated with maropitant require a slightly lower percentage of isoflurane as an inhalational anesthetic. The NK-1 receptors are also identified in different areas of the pain pathways. Therefore, NK-1 receptor antagonists might be effective for managing visceral pain. However, further studies are required to establish the broad therapeutic potential of NK-1 receptor antagonist drugs, such as maropitant in canine medicine. It has been shown that the pain associated with the subcutaneous administration of maropitant is due to metacresol, a preservative used in some formulations. Therefore, the side effects can be eliminated by developing novel maropitant formulations specifically for dogs.
کلیدواژه‌ها
Antiemetic؛ Canine medicine؛ Maropitant؛ Neurokinin-1 receptor antagonist؛ Renal failure
سایر فایل های مرتبط با مقاله
مراجع
  1. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets. 2006;7(8):1043-52.
  2. Trepanier L. Maropitant:Novel Antiemetic .Available from: https://www.cliniciansbrief.com/article/maropitant-novel-antiemetic.
  3. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010;21(12):2316-23.
  4. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291-300.
  5. Garcia-Recio S, Gascon P. Biological and Pharmacological Aspects of the NK1-Receptor. Biomed Res Int. 2015;2015:495704.
  6. Johnson MB, Young AD, Marriott I. The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders. Front Cell Neurosci. 2016;10:296.
  7. Munoz M, Rosso M, Gonzalez A, Saenz J, Covenas R. The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile. Peptides. 2010;31(9):1643-8.
  8. Baum RP. Therapeutic Nuclear Medicine. Heidelberg, Germany: Springer; 2014.
  9. Hoover DB, Chang Y, Hancock JC, Zhang L. Actions of tachykinins within the heart and their relevance to cardiovascular disease. Jpn J Pharmacol. 2000;84(4):367-73.
  10. Hay Kraus BL. Spotlight on the perioperative use of maropitant citrate. Vet Med (Auckl). 2017;8:41-51.
  11. Morris R, Cheunsuang O, Stewart A, Maxwell D. Spinal dorsal horn neurone targets for nociceptive primary afferents: do single neurone morphological characteristics suggest how nociceptive information is processed at the spinal level. Brain Res Brain Res Rev. 2004;46(2):173-90.
  12. Hay Kraus BL. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs. J Am Vet Med Assoc. 2014;245(9):1015-20.
  13. Poma A, Christensen J, Davis J, Kansra V, Martell RE, Hedley ML. Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. Am J Clin Oncol. 2014;32(15):20690.
  14. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, et al. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016;57:23-30.
  15. Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). SCC. 2014;22(2):469-77.
  16. Schank JR, Heilig M. Substance P and the Neurokinin-1 Receptor: The New CRF. Int Rev Neurobiol. 2017;136:151-75.
  17. Polidoro G, Giancola F, Fracassi F, Pietra M, Bettini G, Asti M, et al. Substance P and the neurokinin-1 receptor expression in dog ileum with and without inflammation. Res Vet Sci. 2017;114:297-307.
  18. Benchaoui HA, Cox SR, Schneider RP, Boucher JF, Clemence RG. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007;30(4):336-44.
  19. Elwood C, Devauchelle P, Elliott J, Freiche V, German AJ, Gualtieri M, et al. Emesis in dogs: a review. J Small Anim Pract. 2010;51(1):4-22.
  20. Sedlacek HS, Ramsey DS, Boucher JF, Eagleson JS, Conder GA, Clemence RG. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. J Vet Pharmacol Ther. 2008;31(6):533-7.
  21. Ibrahim MA, Preuss CV. Antiemetic Neurokinin-1 Receptor Blockers. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
  22. Lefebvre H, Ferré J, Watson A. Effect of Renal Failure on Gastrointestinal Physiology in Dogs  Available from : https://www.vin.com/apputil/content/defaultadv1.aspx?id=3846282&pid=11147.
  23. Quimby JM, Brock WT, Moses K, Bolotin D, Patricelli K. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial. J Feline Med Surg. 2015;17(8):692-7.
  24. Ramsey DS, Kincaid K, Watkins JA, Boucher JF, Conder GA, Eagleson JS, et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008;31(6):538-43.
  1. Sullivan LA, Lenberg JP, Boscan P, Hackett TB, Twedt DC. Assessing the Efficacy of Maropitant Versus Ondansetron in the Treatment of Dogs with Parvoviral Enteritis. J Am Anim Hosp Assoc. 2018;54(6):338-43.
  2. de la Puente-Redondo VA, Siedek EM, Benchaoui HA, Tilt N, Rowan TG, Clemence RG. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. J Small Anim Pract. 2007;48(2):93-8.
  3. de la Puente-Redondo VA, Tilt N, Rowan TG, Clemence RG. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res. 2007;68(1):48-56.
  4. Cartagena-Albertus JC, Engel Manchado J, Moise A, Moya Garcia S, Montoya Alonso JA. Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel. Am J Vet Res. 2019;80(6):601-6.
  5. Schmitz S, Fink T, Failing K, Borsch C, Kunz C, Clemence R, et al. Effects of the neurokinin-1 antagonist maropitant on canine gastric emptying assessed by radioscintigraphy and breath test. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2016;44(3):163-9.
  6. Peters RM, Goldstein RE, Erb HN, Njaa BL. Histopathologic features of canine uremic gastropathy: a retrospective study. J Vet Intern Med. 2005;19(3):315-20.
  7. Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38(2):99-103.
  8. Sanderson S. Current concepts for management of chronic renal failure in dogs: early diagnosis and supportive care.  [updated 2008. Available from: https://www.dvm360.com/view/current-concepts-management-chronic-renal-failure-dogs-early-diagnosis-and-supportive-care-proceeding.
  9. Borison HL, Hebertson LM. Role of medullary emetic chemoreceptor trigger zone (CT zone) in postnephrectomy vomiting in dogs. Am J Physiol. 1959;197:850-2.
  10. Goldstein R, Marks S, Kass P, Cowgill L. Gastrin concentrations in plasma of cats with chronic renal failure. J Am Vet Med Assoc. 1998;213(6):826-8.
  1. Hickman MA, Cox SR, Mahabir S, Miskell C, Lin J, Bunger A, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther. 2008;31(3):220-9.
  2. Cheville NF. Uremic gastropathy in the dog. Vet Pathol. 1979;16(3):292-309.
  3. Colby ED, McCarthy LE, Borison HL. Emetic action of xylazine on the chemoreceptor trigger zone for vomiting in cats. J Vet Pharmacol Ther. 1981;4(2):93-6.
  4. Mathis A, Lee K, Alibhai HI. The use of maropitant to prevent vomiting induced by epidural administration of preservative free morphine through an epidural catheter in a dog. Vet Anaesth Analg. 2011;38(5):516-7.
  5. Lorenzutti A, Martín-Flores M, Litterio N, Himelfarb M, Invaldi S, Zarazaga M. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. Can Vet J. 2017;58(1):35-8.
  6. Lorenzutti AM, Martin-Flores M, Litterio NJ, Himelfarb MA, Zarazaga MP. Evaluation of the antiemetic efficacy of maropitant in dogs medicated with morphine and acepromazine. Vet Anaesth Analg. 2016;43(2):195-8.
  7. Marquez M, Boscan P, Weir H, Vogel P, Twedt DC. Comparison of NK-1 Receptor Antagonist (Maropitant) to Morphine as a Pre-Anaesthetic Agent for Canine Ovariohysterectomy. PLoS One. 2015;10(10):0140734.
  1. Claude AK, Dedeaux A, Chiavaccini L, Hinz S. Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs. J Vet Intern Med. 2014;28(5):1414-7.
  2. Alvillar BM, Boscan P, Mama KR, Ferreira TH, Congdon J, Twedt DC. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012;39(2):201-5.
  3. Fukui S, Ooyama N, Tamura J, Umar MA, Ishizuka T, Itami T, et al. Interaction between maropitant and carprofen on sparing of the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs. J Vet Med Sci. 2017;79(3):502-8.
  4. Boscan P, Monnet E, Mama K, Twedt DC, Congdon J, Steffey EP. Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs. Am J Vet Res. 2011;72(12):1576-9.
  5. Deckers N, Ruigrok CA, Verhoeve HP, Lourens N. Comparison of pain response after subcutaneous injection of two maropitant formulations to beagle dogs. Vet Rec Open. 2018;5(1):000262.
47.          Narishetty S, Galvan B, Coscarelli E, Aleo  M, Fleck T, Humphrey W, et al. Effect of refrigeration of the antiemetic Cerenia (maropitant) on pain on injection. Vet Ther. 2009;10(3):93-102.

آمار
تعداد مشاهده مقاله: 4,814
تعداد دریافت فایل اصل مقاله: 4,331


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب